

COMMENTARY TO HABILITATION THESIS¹

Applicant: Lenka Součková, PharmD., Ph.D.

Habilitation Thesis: Building the ecosystem that makes investigator-initiated clinical trials possible.

Institution: Centre of Excellence CREATIC, Faculty of Medicine, Masaryk University

Programme: Pharmacology

Characteristics of the Investigated Matter

The habilitation thesis presents an integrative analysis of investigator-initiated and non-commercial clinical research from a systems perspective. Its central premise is that clinically relevant academic research cannot be understood only through the quality of an individual protocol or trial. The feasibility, quality and eventual impact of non-commercial clinical trials depend on the interaction of methodology, regulation, research infrastructure, funding, professional competence, data and technology, multidisciplinary collaboration, patient involvement, and mechanisms that translate evidence into clinical practice and public health.

The work therefore differs from a disease-specific habilitation thesis. It brings together clinical pharmacology, comparative effectiveness research, precision medicine, advanced therapies, methodological and regulatory research, European research infrastructures, capacity building, evidence transparency, patient and public involvement, and public-health evaluation. These areas are treated as complementary components of one research continuum extending from clinical need and formulation of the research question through study design, regulatory and infrastructural support, trial delivery and evidence generation to implementation and patient or public-health impact.

The thesis is based on 23 scholarly works. Their integration is used to develop an original conceptual framework of the non-commercial clinical research ecosystem. The framework extends the conventional study-centred view of clinical trials and describes how successive stages of the research pathway are supported by cross-cutting enablers such as sustainable funding, capacity building, multidisciplinary collaboration, data and technology, and national and European research networks.

Main Objectives of the Thesis

- Examine methodological approaches supporting the design and conduct of clinically relevant non-commercial clinical trials.
- Analyse regulatory, financial, infrastructural, organisational and capacity-related factors influencing their feasibility and quality.
- Demonstrate the contribution of non-commercial clinical research to comparative effectiveness research, optimisation of existing therapies, precision medicine and advanced therapies.
- Examine the roles of evidence transparency, patient and public involvement, and implementation in translating research findings into healthcare.
- Synthesise these dimensions into an integrated conceptual framework of the non-commercial clinical research ecosystem.

¹ The commentary must correspond to standard expectations in the field and must include a brief characteristic of the investigated matter, objectives of the work, employed methodologies, obtained results and, in case of co-authored works, a passage characterising the applicant's contribution in terms of both quality and content.

Employed Methodologies

The body of work deliberately encompasses a broad methodological spectrum reflecting the diversity of questions addressed by non-commercial clinical research. It includes systematic searches of clinical-trial registries and analyses of funding and research-policy environments; analyses of barriers to multinational academic drug-repurposing trials; evaluation of educational and capacity-building programmes; methodological reviews of innovative trial designs; pragmatic and comparative effectiveness trials; prospective randomised procedural research; pharmacokinetic investigation with population pharmacokinetic modelling; biomarker-driven and translational clinical studies; analyses of publication and recruitment failure; multicentre real-world vaccine-effectiveness studies; and evaluations of national and European clinical-research networks.

Clinical examples range from intensive care and cardiovascular medicine to thoracic surgery, neuro-oncology, epilepsy, paediatric oncology and infectious diseases. The methodological diversity is intentional: the thesis argues that high-quality non-commercial research requires selection of a design appropriate to the clinical question, patient population and evidence gap, while remaining scientifically valid, operationally feasible and relevant to routine healthcare.

Obtained Results and Principal Scientific Contributions

1. Structural determinants of sustainable non-commercial research

Analyses of the Czech and Portuguese research environments and of paediatric non-commercial trials showed that funding structures, institutional support and continuity of financing materially influence the ability to initiate, complete and publish academic clinical research. Work on rare-disease drug repurposing broadened this finding by identifying interacting regulatory, organisational, manufacturing, ethical and infrastructural barriers. The CONSCIOUS II programme further showed the importance of developing practical methodological, regulatory and operational competence among investigators and research professionals.

2. Methodological diversity and clinically driven evidence generation

The clinical studies demonstrate how investigator-initiated research can answer questions arising directly from clinical practice. COINN and BLUEPAT illustrate pragmatic comparative and procedural research; COL-ECMO2022 addresses altered drug disposition during extracorporeal support; and DAPT-SHOCK-AMI represents a large randomised comparison in a critically ill cardiovascular population. Earlier pharmacological studies identified impaired clopidogrel bioavailability after cardiopulmonary resuscitation and clinically relevant drug losses during nasogastric administration, illustrating how academic research can refine the use and delivery of established therapies.

3. Translational and precision medicine

GlioMET and PRECISE demonstrate complementary approaches to biomarker-informed and personalised clinical research, while the dendritic-cell study integrates patient selection, biological starting material, GMP manufacturing, functional immunology and clinical investigation. The latter showed that preceding anticancer therapy can impair dendritic-cell manufacturing and function, linking patient treatment history directly with the quality of a personalised cell-based medicinal product.

4. Evidence generation, transparency and public-health research

The analysis of paediatric randomised trials identified incomplete recruitment and non-publication as important threats to the completeness and efficiency of the evidence base. The I-MOVE/VEBIS studies demonstrate the complementary role of harmonised multinational observational research in generating repeated real-world evidence on vaccine effectiveness as circulating variants, population immunity and epidemiological conditions change.

5. Research infrastructures, capacity and participation

Work on ECRIN, CZECRIN, and the VACCELERATE Site Network and Volunteer Registry illustrates how national disease-oriented networks and European infrastructures can convert distributed clinical expertise and recruitment potential into coordinated research capacity. The study of Czech clinical-trial coordinators highlights the importance of a trained and professionally recognised research workforce. The VACCELERATE communication toolkit and the work on Patient and Public Involvement extend this perspective to public communication and meaningful partnership with patients throughout the research lifecycle.

Applicant's Contribution and Integrative Scientific Contribution

The publications document a long-term scientific trajectory from clinical pharmacology and investigator-initiated studies towards methodology, regulatory science, research infrastructures, capacity building, patient engagement and public-health evaluation. The applicant contributes across clinical, methodological and system-level research and uses this body of work to formulate an integrated interpretation of how non-commercial clinical research functions across its full lifecycle.

The principal integrative contribution of the habilitation thesis is the conceptual framework of the non-commercial clinical research ecosystem. Rather than treating methodology, regulation, infrastructure, funding, professional competence, patient involvement and implementation as independent topics, the framework places them in an interconnected research continuum. Clinical need and the research question initiate the pathway; methodology, regulatory and infrastructural support enable study preparation and delivery; evidence generation, transparency and patient involvement influence the value and usability of the results; and implementation determines whether evidence can contribute to healthcare and public-health impact.

This synthesis provides coherence to a deliberately heterogeneous publication portfolio. The common scientific question is not one disease or intervention, but how clinically relevant questions can be transformed into feasible, rigorous and patient-centred research and how the resulting evidence can be translated into healthcare. In this respect, the thesis positions investigator-initiated and non-commercial clinical trials as an integral component of a continuously learning clinical-research and healthcare ecosystem.

[1] ¹² MADEIRA, C., L. HORAVOVA, F. DOS SANTOS, J. R. BATUCA, K. NEBESKA, L. SOUCKOVA, C. KUBIAK, J. DEMOTES, R. DEMLOVA and E. C. MONTEIRO. Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes. *Therapeutic Innovation & Regulatory Science* [online]. 2021, **55**(5), 966–978. ISSN 2168-4804. Available at: doi:10.1007/s43441-021-00293-w

Document Type: Article; IF = 1,337; median IF PHARMACOLOGY & PHARMACY – 3,580; according to IF PHARMACOLOGY & PHARMACY Q4; according to AIS PHARMACOLOGY & PHARMACY Q4

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
80	50	50	100

² Bibliographic record of a published scientific result, which is part of the habilitation thesis.

[2] HORAVOVA, L., K. NEBESKA, L. SOUCKOVA, R. DEMLOVA and P. BABULA. The Current Status of European and National Financial Sources for Clinical Research and Their Impact on Paediatric Non-commercial Clinical Trials: A Case Study of the Czech Republic. *Therapeutic Innovation & Regulatory Science* [online]. 2020, **54**(6), 1461–1472. ISSN 2168-4804. Available at: doi:10.1007/s43441-020-00173-9

Document Type: Article; IF = 1,778; median IF PHARMACOLOGY & PHARMACY – 3,448; according to IF PHARMACOLOGY & PHARMACY Q4; according to AIS PHARMACOLOGY & PHARMACY Q4

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
50	100	80	100

[3] DEL ALAMO, Marta, Christoph BUHRER, Dirk FISHER, Matthias GRIESE, Paul LINGOR, Giovanni PALLADINI, Nicolas SIREAU, Virginie HIVERT, Luca SANGIORGI, Florence GUILLOT, Julianne HALFTERMEYER, Lenka SOUCKOVA, Kristyna NOSKOVA and Regina DEMLOVA. Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases. *Trials* [online]. 2022, **23**(1, Article 783). ISSN 1745-6215. Available at: doi:10.1186/s13063-022-06713-y

Document Type: Article; IF = 2,500; median IF MEDICINE, RESEARCH & EXPERIMENTAL – 4,000; according to IF MEDICINE, RESEARCH & EXPERIMENTAL Q3; according to AIS MEDICINE, RESEARCH & EXPERIMENTAL Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
60	20	60	80

[4] RYCHLICKOVA, Jitka, Zora CECHOVA, Viktoria NAGY, Katerina NEBESKA, Lenka SOUCKOVA, Stephane MOULY, Gabor Laszlo KOVACS, Christine KUBIAK, Eva TAKACS, Tiago H. MOREIRA DE OLIVEIRA, Marco PAINHO, Emilia C. MONTEIRO, Sara MAIA, Joana BATUCA and Frances SHIELY. Enhancing pragmatic competence in investigator-initiated clinical trials: structure and evaluation of the CONSCIOUS II training programme. *Bmc Medical Education* [online]. 2025, **25**(1, Article 502). ISSN 1472-6920. Available at: doi:10.1186/s12909-025-07054-5

Document Type: Article; IF = 4,200; median IF EDUCATION & EDUCATIONAL RESEARCH – 1,400; according to IF EDUCATION & EDUCATIONAL RESEARCH Q1; according to AIS EDUCATION & EDUCATIONAL RESEARCH Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
40	30	50	50

[5] PAPIEŽ, Adriána, Lenka SOUČKOVÁ and Jitka RYCHLÍČKOVÁ. Innovative clinical trial designs; [Inovativní designy klinických studií]. *Klinická Farmakologie a Farmacie* [online]. 2026, **40**(2), 97–101. ISSN 1212-7973. Available at: doi:10.36290/far.2026.024

Document Type: Article; Category: Pharmaceutical Science – SJR Q4; Pharmacology – SJR Q4; Pharmacy – SJR Q4

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
20	100	30	80

[6] HRDY, Ondrej, Kamil VRBICA, Eva STRAZEVSKA, Petr SUK, **Lenka SOUCKOVA**, Radka STEPANOVA, Igor SAS and Roman GAL. Comparison of continuous versus intermittent enteral nutrition in critically ill patients (COINN): study protocol for a randomized comparative effectiveness trial. *Trials* [online]. 2020, **21**(1, Article 955). ISSN 1745-6215. Available at: doi:10.1186/s13063-020-04866-2

Document Type: Article; IF = 2,279; median IF MEDICINE, RESEARCH & EXPERIMENTAL – 4,036; according to IF MEDICINE, RESEARCH & EXPERIMENTAL Q4; according to AIS MEDICINE, RESEARCH & EXPERIMENTAL Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
40	80	90	20

[7] CHOVANEC, Zdenek, Vladimir CERVENAK, Ivan CUNDRLE, Michal SITINA, Jiri VANICEK, Alena BERKOVA, Tomas HANSLIK, Igor PENKA and **Lenka SOUCKOVA** ***(corresponding author)***. Labelling of subpleural pulmonary nodules with blue dye and contrast agents under CT-guided control and subsequent video-assisted thoracoscopic resection: the BLUEPAT prospective randomised study. *Trials* [online]. 2026, **27**(1, Article 428). ISSN 1745-6215. Available at: doi:10.1186/s13063-026-09748-7

Document Type: Article; IF = 2,100; median IF MEDICINE, RESEARCH & EXPERIMENTAL – 3,000; according to IF MEDICINE, RESEARCH & EXPERIMENTAL Q3; according to AIS MEDICINE, RESEARCH & EXPERIMENTAL Q2 (data 2025)

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
60	50	90	100

[8] SUK, Pavel, Jitka RYCHLICKOVA, **Lenka SOUCKOVA**, Vendula KUBICKOVA and Karel URBANEK. Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: protocol for the COL-ECMO2022 trial - a prospective, non-randomised, open-label phase IV pharmacokinetic clinical trial. *Bmj Open* [online]. 2023, **13**(7). ISSN 2044-6055. Available at: doi:10.1136/bmjopen-2023-071649

Document Type: Article; IF = 2,400; median IF MEDICINE, GENERAL & INTERNAL – 1,100; according to IF MEDICINE, GENERAL & INTERNAL Q1; according to AIS MEDICINE, GENERAL & INTERNAL Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
50	10	60	20

[9] LAKOMY, Radek, Martina LOJOVA, **Lenka SOUCKOVA**, Ludmila HYNKOVA, Katerina POLACHOVA, Jiri VASINA, Regina DEMLOVA, Alexandr POPRACH, Jiri SANA, Tomas PROCHAZKA, Martin SMRCKA, Pavel FADRUS, Radim JANCALEK, Iveta SELINGEROVA, Renata BELANOVA, Pavel SLAMPA, Petr POSPISIL and Tomas KAZDA. 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression:

nonrandomized, open label, prospective clinical trial (GliOMET). *Bmc Cancer* [online]. 2024, **24**(1, Article 736). ISSN 1471-2407. Available at: doi:10.1186/s12885-024-12469-2

Document Type: Article; IF = 3,400; median IF ONCOLOGY – 2,800; according to IF ONCOLOGY Q2; according to AIS ONCOLOGY Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
60	20	50	80

[10] DOLEZALOVA, Irena, Eva KORITAKOVA, **Lenka SOUCKOVA**, Jan CHRASTINA, Jan CHLADEK, Radka STEPANOVA and Milan BRAZDIL. Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design. *Frontiers In Neurology* [online]. 2022, **13**(839163, Article 839163). ISSN 1664-2295. Available at: doi:10.3389/fneur.2022.839163

Document Type: Article; IF = 3,400; median IF CLINICAL NEUROLOGY – 3,200; according to IF CLINICAL NEUROLOGY Q2; according to AIS CLINICAL NEUROLOGY Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
80	0	40	60

[11] HLA VACKOVA, Eva, Katerina PILATOVA, Dasa CERNA, Iveta SELINGEROVA, Peter MUDRY, Pavel MAZANEK, Lenka FEDOROVA, Jana MERHAUTOVA, Lucie JURECKOVA, Lukas SEMERAD, Rita PACASOVA, Lucie FLAJ SAROVA, **Lenka SOUCKOVA**, Regina DEMLOVA, Jaroslav STERBA, Dalibor VALIK and Lenka ZDRAZILOVA-DUBSKA. Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome. *Frontiers In Oncology* [online]. 2019, **9**(1034, Article 1034). ISSN 2234-943X. Available at: doi:10.3389/fonc.2019.01034

Document Type: Article; IF = 4,848; median IF ONCOLOGY – 3,297; according to IF ONCOLOGY Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
50	0	30	40

[12] NEBESKA, Katerina, **Lenka SOUCKOVA** **(corresponding author)**, Radka STEPANOVA and Regina DEMLOVA. Exploring the publication gap in pediatric randomized clinical trials: completed vs. uncompleted pediatric clinical trials. *Frontiers In Medicine* [online]. 2025, **12**(1590125, Article 1590125). ISSN 2296-858X. Available at: doi:10.3389/fmed.2025.1590125

Document Type: Article; IF = 3,600; median IF MEDICINE, GENERAL & INTERNAL – 1,200; according to IF MEDICINE, GENERAL & INTERNAL Q1; according to AIS MEDICINE, GENERAL & INTERNAL Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
50	100	80	100

[13] ROSE, Angela M. C., Nathalie NICOLAY, Virginia Sandonis MARTIN, Clara MAZAGATOS, Goranka PETROVIC, F. Annabel NIESSEN, Ausenda MACHADO, Odile LAUNAY, Sarah DENAYER, Lucie SEYLER, Joaquin BARUCH, Cristina BURGUI, Isabela I. LOGHIN, Lisa DOMEGAN, Roberta VAIKUTYTE, Petr HUSA, George PANAGIOTAKOPOULOS, Nassera AOUALI, Ralf DUERRWALD, Jennifer HOWARD, Francisco POZO, Bartolome SASTRE-PALOU, Diana NONKOVIC, Mirjam J. KNOL, Irina KISLAYA, Liem Binh Luong NGUYEN, Nathalie BOSSUYT, Thomas DEMUYSER, Ausra DZIUGYTE, Ivan MARTINEZ-BAZ, Corneliu POPESCU, Roisin DUFFY, Monika KULIESE, **Lenka SOUCKOVA**, Stella MICHELAKI, Marc SIMON, Janine REICHE, Maria Teresa OTERO-BARROS, Zvezdana Lovric MAKARIC, Patricia C. J. L. BRUIJNING-VERHAGEN, Veronica GOMEZ, Zineb LESIEUR, Cyril BARBEZANGE, Els VAN NEDERVELDE, Maria-Louise BORG, Jesus CASTILLA, Mihaela LAZAR, Joan O'DONNELL, Indre JONIKAITÉ, Regina DEMLOVA, Marina AMERALI, Gil WIRTZ, Kristin TOLKSDORF, Marta VALENCIANO, Sabrina BACCI, Esther KISSLING, I-MOVE-COVID-19 HOSP STUDY TEAM and VEBIS HOSP STUDY TEAM. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021. *Eurosurveillance* [online]. 2023, **28**(47, Article 2300186). ISSN 1560-7917. Available at: doi:10.2807/1560-7917.Es.2023.28.47.2300186

Document Type: Article; IF = 10,000; median IF INFECTIOUS DISEASES – 2,750; according to IF INFECTIOUS DISEASES Q1; according to AIS INFECTIOUS DISEASES Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
90	0	30	20

[14] MC ROSE, Angela, Nathalie NICOLAY, Virginia Sandonis MARTIN, Clara MAZAGATOS, Goranka PETROVIC, Joaquin BARUCH, Sarah DENAYER, Lucie SEYLER, Lisa DOMEGAN, Odile LAUNAY, Ausenda MACHADO, Cristina BURGUI, Roberta VAIKUTYTE, F. Annabel NIESSEN, Isabela I. LOGHIN, Petr HUSA, Nassera AOUALI, George PANAGIOTAKOPOULOS, Kristin TOLKSDORF, Judit Krisztina HORVATH, Jennifer HOWARD, Francisco POZO, Virtudes GALLARDO, Diana NONKOVIC, Ausra DZIUGYTE, Nathalie BOSSUYT, Thomas DEMUYSER, Roisin DUFFY, Liem binh Luong NGUYEN, Irina KISLAYA, Ivan MARTINEZ-BAZ, Giedre GEFENAITE, Mirjam J. KNOL, Corneliu POPESCU, **Lenka SOUCKOVA**, Marc SIMON, Stella MICHELAKI, Janine REICHE, Annamaria FERENCZI, Concepcion DELGADO-SANZ, Zvezdana Lovric MAKARIC, John Paul CAUCHI, Cyril BARBEZANGE, Els VAN NEDERVELDE, Joan O'DONNELL, Christine DURIER, Raquel GUIOMAR, Jesus CASTILLA, Indre JONIKAITÉ, Patricia C. J. L. BRUIJNING-VERHAGEN, Mihaela LAZAR, Regina DEMLOVA, Gil WIRTZ, Marina AMERALI, Ralf DUERRWALD, Mihaly Pal KUNSTAR, Esther KISSLING, Sabrina BACCI, Marta VALENCIANO, I-MOVE-COVID-19 HOSP STUDY and VEBIS HOSP STUDY TEAM. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022. *Eurosurveillance* [online]. 2023, **28**(47, Article 2300187). ISSN 1560-7917. Available at: doi:10.2807/1560-7917.Es.2023.28.47.2300187

Document Type: Article; IF = 10,000; median IF INFECTIOUS DISEASES – 2,750; according to IF INFECTIOUS DISEASES Q1; according to AIS INFECTIOUS DISEASES Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
-----------------------	-----------------	----------------	------------------------

90	0	30	20
----	---	----	----

[15] SELVEKEROVÁ, Šárka, Michaela HANÁKOVÁ, Regina DEMLOVÁ, Kateřina NEBESKÁ, Helena KRIST, Martin DUŠEK, Naděžda PUŠKAŘOVÁ, Pavla NEVOLOVÁ, Petra BRANDEJSOVÁ, Hana DOLEŽALOVÁ, Karin CVIKLIKOVÁ, Johana KREMPOVÁ and **Lenka SOUČKOVÁ** **(corresponding author)**. The Role of the Clinical Research Coordinator in Healthcare Institutions – A Cinderella Among Clinical Trial Experts?; [Role studijního koordinátora v klinickém výzkumu ve zdravotnických zařízeních – popelka mezi experty v klinických studiích?+]. *Klinická Farmakologie a Farmacie* [online]. 2024, **38**(3), 124–131. ISSN 1212-7973. Available at: doi:10.36290/far.2024.020

Document Type: Article; Category: Pharmaceutical Science – SJR Q4; Pharmacology – SJR Q4; Pharmacy – SJR Q4

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
50	100	50	100

[16] SALMANTON-GARCIA, Jon, Pauline WIPFLER, Paula VALLE-SIMON, Christina MERAKOU, Ioannis KOPSIDAS, Ullrich BETHE, Angela STEINBACH, Orly SPIVAK, **Lenka SOUCKOVA**, Maria Amelia MENDONCA, Markela KONIORDOU, Margot HELLEMANS, Jesus FRIAS-INIESTA, Ruth Joanna DAVIS, Imre BARTA, Anna Maria AZZINI, Helena H. ASKLING, Christos D. ARGYROPOULOS, Elena ALVAREZ-BARCO, Murat AKOVA, Marc M. J. BONTEN, Miriam COHEN-KANDLI, Rebecca Jane COX, Robert FLISIAK, Petr HUSA, Ligita JANCORIENE, Alena KOSCALOVA, Odile LAUNAY, Jens LUNDGREN, Patrick MALLON, Laura MARQUES, Pontus NAUCLER, Jordi OCHANDO, Zoi-Dorothea PANA, Evelina TACCONELLI, Krisztina TOTH, Sven TRELLE, Pierre VAN DAMME, Theoklis E. ZAOUTIS, Markus ZEITLINGER, Kerstin ALBUS, Fiona A. STEWART, Sanne H. I. HOFSTRAAT, Patricia BRUIJNING-VERHAGEN, Oliver A. CORNELLY and ACCELERATE CONSORTIUM. VACCCELERATE Site Network: Real-time definition of clinical study capacity in Europe. *Vaccine* [online]. 2023, **41**(26), 3915–3922. ISSN 1873-2518. Available at: doi:10.1016/j.vaccine.2023.05.006

Document Type: Article; IF = 4,500; median IF MEDICINE, RESEARCH & EXPERIMENTAL – 2,700; according to IF MEDICINE, RESEARCH & EXPERIMENTAL Q2; according to AIS MEDICINE, RESEARCH & EXPERIMENTAL Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
70	0	30	40

[17] SALMANTON-GARCIA, Jon, Fiona A. STEWART, Sarah HERINGER, Markela KONIORDOU, Elena ALVAREZ-BARCO, Christos D. ARGYROPOULOS, Sophia C. THEMISTOCLEOUS, Paula VALLE-SIMON, Orly SPIVAK, **Lenka SOUCKOVA**, Christina MERAKOU, Maria Amelia MENDONCA, Ruth Joanna DAVIS, Anna Maria AZZINI, Helena H. ASKLING, Sirkka VENE, Pierre VAN DAMME, Angela STEINBACH, George SHIAMAKKIDES, Danila SEIDEL, Ole F. OLESEN, Evgenia NOULA, Alan MACKEN, Catarina LUIS, Janina LECKLER, Odile LAUNAY, Catherine ISITT, Margot HELLEMANS, Jesus FRIAS-INIESTA, Romina DI MARZO, Antonio J. CARCAS, George BOUSTRAS, Alberto M. BOROBIA, Imre BARTA, Kerstin ALBUS, Murat AKOVA, Jordi OCHANDO, Miriam COHEN-KANDLI, Rebecca

Jane COX, Petr HUSA, Ligita JANCORIENTE, Patrick MALLON, Laura MARQUES, Sibylle C. MELLINGHOFF, Pontus NAUCLER, Evelina TACCONELLI, Krisztina TOTH, Theoklis E. ZAOUTIS, Markus ZEITLINGER, Oliver A. CORNELLY, Zoi-Dorothea PANA and VACCELERATE CONSORTIUM. VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. *Vaccine* [online]. 2022, **40**(31), 4090–4097. ISSN 1873-2518. Available at: doi:10.1016/j.vaccine.2022.05.022

Document Type: Article; IF = 5,500; median IF MEDICINE, RESEARCH & EXPERIMENTAL – 4,000; according to IF MEDICINE, RESEARCH & EXPERIMENTAL Q2; according to AIS MEDICINE, RESEARCH & EXPERIMENTAL Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
80	0	40	20

[18] ARGYROPOULOS, Christos, Janina LECKLER, Jon SALMANTON-GARCIA, Marinos CONSTANTINOU, Alexandra ALEXANDROU, Sophia THEMISTOCLEOUS, Evgenia NOULA, George SHIAMAKKIDES, Andria NEARCHOU, Fiona A. STEWART, Kerstin ALBUS, Markela KONIORDOU, Ioannis KOPSIDAS, Orly SPIVAK, Margot HELLEMANS, Greet HENDRICKX, Ruth Joanna DAVIS, Anna Maria AZZINI, Paula Valle SIMON, Antonio Javier CARCAS-SANSUAN, Helena Hervius ASKLING, Sirkka VENE, Jana Baranda PRELLEZO, Elena ALVAREZ-BARCO, Alan J. MACKEN, Romina DI MARZO, Catarina LUIS, Ole F. OLESEN, Jesus A. Frias INIESTA, Imre BARTA, Krisztina TOTH, Murat AKOVA, Marc M. J. BONTEN, Miriam COHEN-KANDLI, Rebecca Jane COX, **Lenka SOUCKOVA**, Petr HUSA, Ligita JANCORIENTE, Odile LAUNAY, Jens LUNDGREN, Patrick MALLON, Charis ARMEFTIS, Laura MARQUES, Pontus NAUCLER, Jordi OCHANDO, Evelina TACCONELLI, Pierre VAN DAMME, Theoklis ZAOUTIS, Sanne HOFSTRAAT, Patricia BRUIJNING-VERHAGEN, Markus ZEITLINGER, Oliver A. CORNELLY and Zoi Dorothea PANA. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit. *Jmir Public Health And Surveillance* [online]. 2023, **9**(e44491, Article e44491). ISSN 2369-2960. Available at: doi:10.2196/44491

Document Type: Article; IF = 3,500; median IF PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH – 2,200; according to IF PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Q1; according to AIS PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
70	0	40	20

[19] MOTOVSKA, Zuzana, Ota HLINOMAZ, Jan MROZEK, Petr KALA, Tobias GEISLER, Milan HROMADKA, Ibrahim AKIN, Jan PRECEK, Jiri KETTNER, Pavel CERVINKA, Gilles MONTALESCOT, Jiri JARKOVSKY, Jan BELOHLAVEK, Josef BIS, Jan MATEJKA, Alexandra VODZINSKA, Tamilla MUZAFAROVA, Pavol TOMASOV, Alexander SCHEE, Stanislav BARTUS, Andrea ANDRASOVA, Christoph B. OLIVIER, Ales KOVARIK, Petr OSTADAL, Regina DEMLOVA, **Lenka SOUCKOVA**, Ivan VULEV, Zdenek COUFAL, Janusz KOCHMAN, Iuri MARINOV, Jacek KUBICA, Gregory DUCROCQ, Michal KARPISEK, Zdenek KLIMS, Martin HUDEC, Petr WIDIMSKY, Deepak L. BHATT and DAPT SHOCK AMI STUDY GRP. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI

trial. *Eurointervention* [online]. 2024, **20**(20). ISSN 1969-6213. Available at: doi:10.4244/Eij-D-24-00203

Document Type: Article; IF = 9,500; median IF CARDIAC & CARDIOVASCULAR SYSTEMS – 2,200; according to IF CARDIAC & CARDIOVASCULAR SYSTEMS Q1; according to AIS CARDIAC & CARDIOVASCULAR SYSTEMS Q1

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
20	10	50	80

[20] SOUCKOVA, L., R. OPATRILOVA, P. SUK, Jr. CUNDRLE, M. PAVLIK, V. ZVONICEK, O. HLINOMAZ and V. SRAMEK. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). *European Journal Of Clinical Pharmacology* [online]. 2013, **69**(3), 309–317. ISSN 1432-1041. Available at: doi:10.1007/s00228-012-1360-0

Document Type: Review; IF = 2,697; median IF PHARMACOLOGY & PHARMACY – 2,205; according to IF PHARMACOLOGY & PHARMACY Q2; according to AIS PHARMACOLOGY & PHARMACY Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
100	0	100	80

[21] RUZSIKOVA, Adriana, Lenka SOUCKOVA, Pavel SUK, Radka OPATRILOVA, Martina KEJDUSOVA and Vladimir SRAMEK. Quantitative analysis of drug losses administered via nasogastric tube - In vitro study. *International Journal Of Pharmaceutics* [online]. 2015, **478**(1), 368–371. ISSN 1873-3476. Available at: doi:10.1016/j.ijpharm.2014.11.065

Document Type: Article; IF = 3,994; median IF PHARMACOLOGY & PHARMACY – 2,330; according to IF PHARMACOLOGY & PHARMACY Q1; according to AIS PHARMACOLOGY & PHARMACY Q2

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
40	100	40	100

[22] BLAHYNKOVÁ, Hana, Lenka SOUČKOVÁ and Adriána PAPIEŽ. Patient and Public Involvement in clinical research: from regulatory requirements to partnerships with patients; [Patient and Public Involvement v klinickém výzkumu: od regulačních požadavků k partnerské spolupráci s pacienty]. *Klinická Farmakologie a Farmacie* [online]. 2026, **40**(2), 112–115. ISSN 1212-7973. Available at: doi:10.36290/far.2026.025

Document Type: Article; Category: Pharmaceutical Science – SJR Q4; Pharmacology – SJR Q4; Pharmacy – SJR Q4

Experimental work (%)	Supervision (%)	Manuscript (%)	Research direction (%)
30	100	30	100